Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
about
New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeuticsPI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell linesEfficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemiaThe functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemiaDevelopment of Polypeptide-based Nanoparticles for Non-viral Delivery of CD22 RNA Trans-splicing Molecule as a New Precision Medicine Candidate Against B-lineage ALL.Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia.Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.Intracellular Signaling Pathways Involved in Childhood Acute Lymphoblastic Leukemia; Molecular TargetsThe pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells.Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.Control of B lymphocyte development and functions by the mTOR signaling pathways.The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cellsα-2,8-Sialyltransferase Is Involved in the Development of Multidrug Resistance via PI3K/Akt Pathway in Human Chronic Myeloid Leukemia.PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.New Insights into mTOR Signal Pathways in Ovarian-Related Diseases: Polycystic Ovary Syndrome and Ovarian CancerPiperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells.EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia.Pantoprazole Induces Apoptosis of Leukemic Cells by Inhibiting Expression of P-Glycoprotein/Multidrug Resistance-Associated Protein-1 Through PI3K/AKT/mTOR Signaling.Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.
P2860
Q30371980-31A5B4F1-F533-434A-8B6F-B25A7AD3C183Q33618630-F65DB0AC-A0E0-40FE-B322-445FF74CA8AEQ34786480-FA65CF79-1005-47B1-A937-42F1DA7B1808Q35547514-334B722D-879C-47A3-9ACA-5725B3C98597Q35947493-7BE8E45E-2958-4A87-9018-CB00CE7B7AFBQ36214081-3E6B0380-1746-4A48-AB30-9A07168B5BBDQ36544778-0E1D523B-C9CE-42F6-A0CE-3F05FAEDDCEBQ36679531-3C4E6628-51FB-4C28-BC70-4C992C88B844Q36992184-A6596437-B758-40D1-8073-6E515CC0CBE3Q37021907-8FFD57B3-5FFB-4D8A-ACBB-CE6845849445Q37353724-B420D965-333A-4C2A-A289-9ECB22E22994Q37644988-B91393B4-0849-4F6A-BC11-C35D82DCCEE3Q38218128-AA41BA83-8387-4325-BB31-5D1670E85D7CQ38521775-52C3A52A-8F8E-448C-BC55-0351D778AE82Q38674507-9CE12126-4A14-4FAF-ABBB-46F25A7CFD97Q38871688-590EA19C-DA38-465D-A576-4E5CE0A0B01EQ38889539-CDF63FE0-3B2E-48FE-912E-6E4CA2894609Q38940615-3EF65A4E-D098-4B63-85E6-7D508588B2E3Q38949674-904C63AA-B70C-4992-ABAB-692856FEDD68Q42144129-429F344B-0B02-4CB4-8D22-B7544C93E0BCQ42167869-895565BF-D6ED-49B9-848E-C152B743E5A1Q42175070-F1731C73-1663-4AB7-BBC5-7689E5F0B6B7Q44018556-AE3BC626-C48B-4771-B72D-EEB577250EFEQ44813914-CB84167E-11D3-4AD3-B3FB-8986FADF29B0Q47597731-1D9536E0-F790-45D6-A8DE-A725EA490D9BQ49887884-DA1CC267-FFE6-4527-BEC8-00233A4F0423
P2860
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Differential effects of select ...... acute lymphoblastic leukemia.
@en
Differential effects of select ...... acute lymphoblastic leukemia.
@nl
type
label
Differential effects of select ...... acute lymphoblastic leukemia.
@en
Differential effects of select ...... acute lymphoblastic leukemia.
@nl
prefLabel
Differential effects of select ...... acute lymphoblastic leukemia.
@en
Differential effects of select ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P1433
P1476
Differential effects of select ...... n acute lymphoblastic leukemia
@en
P2093
Bart A Nijmeijer
Heike Pfeifer
J H Frederik Falkenburg
Marcus Liebermann
Susanne Badura
Sylvia Wystub
Tamara Tesanovic
P2860
P304
P356
10.1371/JOURNAL.PONE.0080070
P407
P577
2013-11-14T00:00:00Z